Loading…
Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study
Background Studies concerning prognostic factors specific for alendronate‐related osteonecrosis of the jaws (ONJ) are rare. Methods We surveyed a cohort of 100 osteoporotic patients with 111 alendronate‐related ONJ lesions treated during a 4‐year period. Prognostic values of clinical variables and s...
Saved in:
| Published in: | Head & neck 2013-12, Vol.35 (12), p.1787-1795 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4175-7ad7ee83bc307f91a0058783ef399326de68efa8740f70caccd1ef6631957f843 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4175-7ad7ee83bc307f91a0058783ef399326de68efa8740f70caccd1ef6631957f843 |
| container_end_page | 1795 |
| container_issue | 12 |
| container_start_page | 1787 |
| container_title | Head & neck |
| container_volume | 35 |
| creator | Lee, Jang-Jaer Cheng, Shih-Jung Wang, Jai-Jen Chiang, Chun-Pin Chang, Hao-Hueng Chen, Hsin-Ming Kok, Sang-Heng |
| description | Background
Studies concerning prognostic factors specific for alendronate‐related osteonecrosis of the jaws (ONJ) are rare.
Methods
We surveyed a cohort of 100 osteoporotic patients with 111 alendronate‐related ONJ lesions treated during a 4‐year period. Prognostic values of clinical variables and serum markers of bone turnover were assessed by univariate and multivariate analyses.
Results
The cumulative complete response rate at 6 months was 48.65%. Serum bone‐specific alkaline phosphatase (BSAP) level >10 μg/L, lesion depth ≦ 10 mm, and lesions in anterior regions denoted a better chance of healing within 6 months and the adjusted hazard ratios were 2.48 (95% confidence interval [CI], 1.41–4.37), 2.71 (95% CI, 1.57–4.70), and 3.94 (95% CI, 1.87–8.30), respectively.
Conclusions
Early discovery of lesions and prevention of their deeper extension are crucial for improving the prognosis of alendronate‐related ONJ. A higher pretreatment level of BSAP indicates a better prognosis. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1787–1795, 2013 |
| doi_str_mv | 10.1002/hed.23235 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1459560010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1459560010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4175-7ad7ee83bc307f91a0058783ef399326de68efa8740f70caccd1ef6631957f843</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS0EoqVw4AsgS1zgkHaccWKHW9U_W6QCBxaQuFiuM-5mycbFTlT22-OwXQ5InMYe_eZp3jzGXgo4FgDlyYra4xJLrB6xQwGNKgClejy_JRYISh6wZymtAQBrWT5lBxkFXdVwyDaX1o0hJn4Xqe3c2A23fFxR_obbIaQu8eB5iLbntqehjWGwIxWR-lxaHtJIYSAX9-Q8urb36R0_5bLYko3chVWII0_j1G6fsyfe9olePNQj9uXyYnl2VVx_Wrw_O70unBSqKpRtFZHGG5eX942wAJVWGslj02BZt1Rr8lYrCV6Bs861gnxdo2gq5bXEI_Zmp5tt_JwojWbTJUd9bwcKUzJCVk22DwIy-vofdB2mOOTtZkojCqx1pt7uqNlqiuTNXew2Nm6NADNnYHIG5k8GmX31oDjdbHJ3T-6PnoGTHXDf9bT9v5K5ujjfSxa7iS4f_NffCRt_mFqhqsy3jwuz-FAtP58vv5uv-BuKyp9v</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1458331368</pqid></control><display><type>article</type><title>Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Lee, Jang-Jaer ; Cheng, Shih-Jung ; Wang, Jai-Jen ; Chiang, Chun-Pin ; Chang, Hao-Hueng ; Chen, Hsin-Ming ; Kok, Sang-Heng</creator><creatorcontrib>Lee, Jang-Jaer ; Cheng, Shih-Jung ; Wang, Jai-Jen ; Chiang, Chun-Pin ; Chang, Hao-Hueng ; Chen, Hsin-Ming ; Kok, Sang-Heng</creatorcontrib><description>Background
Studies concerning prognostic factors specific for alendronate‐related osteonecrosis of the jaws (ONJ) are rare.
Methods
We surveyed a cohort of 100 osteoporotic patients with 111 alendronate‐related ONJ lesions treated during a 4‐year period. Prognostic values of clinical variables and serum markers of bone turnover were assessed by univariate and multivariate analyses.
Results
The cumulative complete response rate at 6 months was 48.65%. Serum bone‐specific alkaline phosphatase (BSAP) level >10 μg/L, lesion depth ≦ 10 mm, and lesions in anterior regions denoted a better chance of healing within 6 months and the adjusted hazard ratios were 2.48 (95% confidence interval [CI], 1.41–4.37), 2.71 (95% CI, 1.57–4.70), and 3.94 (95% CI, 1.87–8.30), respectively.
Conclusions
Early discovery of lesions and prevention of their deeper extension are crucial for improving the prognosis of alendronate‐related ONJ. A higher pretreatment level of BSAP indicates a better prognosis. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1787–1795, 2013</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.23235</identifier><identifier>PMID: 23508560</identifier><identifier>CODEN: HEANEE</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; alendronate ; Alendronate - adverse effects ; Alkaline Phosphatase - blood ; Amoxicillin - therapeutic use ; Amoxicillin-Potassium Clavulanate Combination - therapeutic use ; Anti-Bacterial Agents - therapeutic use ; Biomarkers - blood ; Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology ; Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy ; Bone Density Conservation Agents - adverse effects ; Bone Remodeling ; BSAP ; Chlorhexidine - therapeutic use ; Clindamycin - therapeutic use ; Cohort Studies ; Collagen Type I - blood ; CTX ; Debridement ; Female ; Humans ; Male ; Middle Aged ; Mouthwashes - therapeutic use ; Multivariate Analysis ; ONJ ; osteoporosis ; Osteoporosis - drug therapy ; Peptides - blood ; Prognosis ; Retrospective Studies</subject><ispartof>Head & neck, 2013-12, Vol.35 (12), p.1787-1795</ispartof><rights>Copyright © 2013 Wiley Periodicals, Inc., A Wiley Company</rights><rights>Copyright © 2013 Wiley Periodicals, Inc., A Wiley Company.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4175-7ad7ee83bc307f91a0058783ef399326de68efa8740f70caccd1ef6631957f843</citedby><cites>FETCH-LOGICAL-c4175-7ad7ee83bc307f91a0058783ef399326de68efa8740f70caccd1ef6631957f843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23508560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Jang-Jaer</creatorcontrib><creatorcontrib>Cheng, Shih-Jung</creatorcontrib><creatorcontrib>Wang, Jai-Jen</creatorcontrib><creatorcontrib>Chiang, Chun-Pin</creatorcontrib><creatorcontrib>Chang, Hao-Hueng</creatorcontrib><creatorcontrib>Chen, Hsin-Ming</creatorcontrib><creatorcontrib>Kok, Sang-Heng</creatorcontrib><title>Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
Studies concerning prognostic factors specific for alendronate‐related osteonecrosis of the jaws (ONJ) are rare.
Methods
We surveyed a cohort of 100 osteoporotic patients with 111 alendronate‐related ONJ lesions treated during a 4‐year period. Prognostic values of clinical variables and serum markers of bone turnover were assessed by univariate and multivariate analyses.
Results
The cumulative complete response rate at 6 months was 48.65%. Serum bone‐specific alkaline phosphatase (BSAP) level >10 μg/L, lesion depth ≦ 10 mm, and lesions in anterior regions denoted a better chance of healing within 6 months and the adjusted hazard ratios were 2.48 (95% confidence interval [CI], 1.41–4.37), 2.71 (95% CI, 1.57–4.70), and 3.94 (95% CI, 1.87–8.30), respectively.
Conclusions
Early discovery of lesions and prevention of their deeper extension are crucial for improving the prognosis of alendronate‐related ONJ. A higher pretreatment level of BSAP indicates a better prognosis. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1787–1795, 2013</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>alendronate</subject><subject>Alendronate - adverse effects</subject><subject>Alkaline Phosphatase - blood</subject><subject>Amoxicillin - therapeutic use</subject><subject>Amoxicillin-Potassium Clavulanate Combination - therapeutic use</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bone Remodeling</subject><subject>BSAP</subject><subject>Chlorhexidine - therapeutic use</subject><subject>Clindamycin - therapeutic use</subject><subject>Cohort Studies</subject><subject>Collagen Type I - blood</subject><subject>CTX</subject><subject>Debridement</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mouthwashes - therapeutic use</subject><subject>Multivariate Analysis</subject><subject>ONJ</subject><subject>osteoporosis</subject><subject>Osteoporosis - drug therapy</subject><subject>Peptides - blood</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kU9v1DAQxS0EoqVw4AsgS1zgkHaccWKHW9U_W6QCBxaQuFiuM-5mycbFTlT22-OwXQ5InMYe_eZp3jzGXgo4FgDlyYra4xJLrB6xQwGNKgClejy_JRYISh6wZymtAQBrWT5lBxkFXdVwyDaX1o0hJn4Xqe3c2A23fFxR_obbIaQu8eB5iLbntqehjWGwIxWR-lxaHtJIYSAX9-Q8urb36R0_5bLYko3chVWII0_j1G6fsyfe9olePNQj9uXyYnl2VVx_Wrw_O70unBSqKpRtFZHGG5eX942wAJVWGslj02BZt1Rr8lYrCV6Bs861gnxdo2gq5bXEI_Zmp5tt_JwojWbTJUd9bwcKUzJCVk22DwIy-vofdB2mOOTtZkojCqx1pt7uqNlqiuTNXew2Nm6NADNnYHIG5k8GmX31oDjdbHJ3T-6PnoGTHXDf9bT9v5K5ujjfSxa7iS4f_NffCRt_mFqhqsy3jwuz-FAtP58vv5uv-BuKyp9v</recordid><startdate>201312</startdate><enddate>201312</enddate><creator>Lee, Jang-Jaer</creator><creator>Cheng, Shih-Jung</creator><creator>Wang, Jai-Jen</creator><creator>Chiang, Chun-Pin</creator><creator>Chang, Hao-Hueng</creator><creator>Chen, Hsin-Ming</creator><creator>Kok, Sang-Heng</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201312</creationdate><title>Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study</title><author>Lee, Jang-Jaer ; Cheng, Shih-Jung ; Wang, Jai-Jen ; Chiang, Chun-Pin ; Chang, Hao-Hueng ; Chen, Hsin-Ming ; Kok, Sang-Heng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4175-7ad7ee83bc307f91a0058783ef399326de68efa8740f70caccd1ef6631957f843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>alendronate</topic><topic>Alendronate - adverse effects</topic><topic>Alkaline Phosphatase - blood</topic><topic>Amoxicillin - therapeutic use</topic><topic>Amoxicillin-Potassium Clavulanate Combination - therapeutic use</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bone Remodeling</topic><topic>BSAP</topic><topic>Chlorhexidine - therapeutic use</topic><topic>Clindamycin - therapeutic use</topic><topic>Cohort Studies</topic><topic>Collagen Type I - blood</topic><topic>CTX</topic><topic>Debridement</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mouthwashes - therapeutic use</topic><topic>Multivariate Analysis</topic><topic>ONJ</topic><topic>osteoporosis</topic><topic>Osteoporosis - drug therapy</topic><topic>Peptides - blood</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Jang-Jaer</creatorcontrib><creatorcontrib>Cheng, Shih-Jung</creatorcontrib><creatorcontrib>Wang, Jai-Jen</creatorcontrib><creatorcontrib>Chiang, Chun-Pin</creatorcontrib><creatorcontrib>Chang, Hao-Hueng</creatorcontrib><creatorcontrib>Chen, Hsin-Ming</creatorcontrib><creatorcontrib>Kok, Sang-Heng</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Jang-Jaer</au><au>Cheng, Shih-Jung</au><au>Wang, Jai-Jen</au><au>Chiang, Chun-Pin</au><au>Chang, Hao-Hueng</au><au>Chen, Hsin-Ming</au><au>Kok, Sang-Heng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2013-12</date><risdate>2013</risdate><volume>35</volume><issue>12</issue><spage>1787</spage><epage>1795</epage><pages>1787-1795</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><coden>HEANEE</coden><abstract>Background
Studies concerning prognostic factors specific for alendronate‐related osteonecrosis of the jaws (ONJ) are rare.
Methods
We surveyed a cohort of 100 osteoporotic patients with 111 alendronate‐related ONJ lesions treated during a 4‐year period. Prognostic values of clinical variables and serum markers of bone turnover were assessed by univariate and multivariate analyses.
Results
The cumulative complete response rate at 6 months was 48.65%. Serum bone‐specific alkaline phosphatase (BSAP) level >10 μg/L, lesion depth ≦ 10 mm, and lesions in anterior regions denoted a better chance of healing within 6 months and the adjusted hazard ratios were 2.48 (95% confidence interval [CI], 1.41–4.37), 2.71 (95% CI, 1.57–4.70), and 3.94 (95% CI, 1.87–8.30), respectively.
Conclusions
Early discovery of lesions and prevention of their deeper extension are crucial for improving the prognosis of alendronate‐related ONJ. A higher pretreatment level of BSAP indicates a better prognosis. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1787–1795, 2013</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>23508560</pmid><doi>10.1002/hed.23235</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2013-12, Vol.35 (12), p.1787-1795 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1459560010 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Aged Aged, 80 and over alendronate Alendronate - adverse effects Alkaline Phosphatase - blood Amoxicillin - therapeutic use Amoxicillin-Potassium Clavulanate Combination - therapeutic use Anti-Bacterial Agents - therapeutic use Biomarkers - blood Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy Bone Density Conservation Agents - adverse effects Bone Remodeling BSAP Chlorhexidine - therapeutic use Clindamycin - therapeutic use Cohort Studies Collagen Type I - blood CTX Debridement Female Humans Male Middle Aged Mouthwashes - therapeutic use Multivariate Analysis ONJ osteoporosis Osteoporosis - drug therapy Peptides - blood Prognosis Retrospective Studies |
| title | Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: A 4-year cohort study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A15%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20predicting%20the%20prognosis%20of%20oral%20alendronate-related%20osteonecrosis%20of%20the%20jaws:%20A%204-year%20cohort%20study&rft.jtitle=Head%20&%20neck&rft.au=Lee,%20Jang-Jaer&rft.date=2013-12&rft.volume=35&rft.issue=12&rft.spage=1787&rft.epage=1795&rft.pages=1787-1795&rft.issn=1043-3074&rft.eissn=1097-0347&rft.coden=HEANEE&rft_id=info:doi/10.1002/hed.23235&rft_dat=%3Cproquest_cross%3E1459560010%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4175-7ad7ee83bc307f91a0058783ef399326de68efa8740f70caccd1ef6631957f843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1458331368&rft_id=info:pmid/23508560&rfr_iscdi=true |